Low-dose aspirin as treatment for central serous chorioretinopathy

Antonio Caccavale1, Filippo Romanazzi1, Manuela Imparato1, Angelo Negri1, Anna Morano2, Fabio Ferentini11Department of Ophthalmology, Hospital C Cant&ugrave;, Abbiategrasso, Milan; 2University Eye Clinic, Foundation IRCCS San Matteo Hospital, Pavia, ItalyPurpose: To evaluate the effectivenes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonio Caccavale, Filippo Romanazzi, Manuela Imparato, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/df09e4699ca4414d864fbdb0844326de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:df09e4699ca4414d864fbdb0844326de
record_format	dspace
spelling	oai:doaj.org-article:df09e4699ca4414d864fbdb0844326de2021-12-02T07:21:21ZLow-dose aspirin as treatment for central serous chorioretinopathy1177-54671177-5483https://doaj.org/article/df09e4699ca4414d864fbdb0844326de2010-08-01T00:00:00Zhttp://www.dovepress.com/low-dose-aspirin-as-treatment-for-central-serous-chorioretinopathy-a4982https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Antonio Caccavale1, Filippo Romanazzi1, Manuela Imparato1, Angelo Negri1, Anna Morano2, Fabio Ferentini11Department of Ophthalmology, Hospital C Cant&ugrave;, Abbiategrasso, Milan; 2University Eye Clinic, Foundation IRCCS San Matteo Hospital, Pavia, ItalyPurpose: To evaluate the effectiveness of low-dose aspirin for the treatment of central serous chorioretinopathy (CSCR).Patients and methods: Patients with classical or multifocal CSCR were treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months. Treated patients were compared with historic controls consisting of patients with classical or multifocal CSCR previously followed up at our institution.Results: Mean visual acuity in the group treated with aspirin started to improve after the first week of therapy and continued to improve throughout the following 3 months. Visual recovery was slower in the untreated control group than in the treated group and achieved better visual acuity between the first and third month from the onset of the disease. There were no adverse events related to the administration of aspirin.Conclusion: The results indicate that treatment with low-dose aspirin may result in more rapid visual rehabilitation with fewer recurrences in patient with CSCR compared with untreated historic controls. The effectiveness of treatment with aspirin supports our hypothesis regarding the role of impaired fibrinolysis and increased platelet aggregation in the choriocapillaris in the pathogenesis of CSCR.Keywords: central serous chorioretinopathy, aspirin, plasminogen activator inhibitor 1, macula Antonio CaccavaleFilippo RomanazziManuela Imparatoet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 899-903 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Antonio Caccavale Filippo Romanazzi Manuela Imparato et al Low-dose aspirin as treatment for central serous chorioretinopathy
description	Antonio Caccavale1, Filippo Romanazzi1, Manuela Imparato1, Angelo Negri1, Anna Morano2, Fabio Ferentini11Department of Ophthalmology, Hospital C Cant&ugrave;, Abbiategrasso, Milan; 2University Eye Clinic, Foundation IRCCS San Matteo Hospital, Pavia, ItalyPurpose: To evaluate the effectiveness of low-dose aspirin for the treatment of central serous chorioretinopathy (CSCR).Patients and methods: Patients with classical or multifocal CSCR were treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months. Treated patients were compared with historic controls consisting of patients with classical or multifocal CSCR previously followed up at our institution.Results: Mean visual acuity in the group treated with aspirin started to improve after the first week of therapy and continued to improve throughout the following 3 months. Visual recovery was slower in the untreated control group than in the treated group and achieved better visual acuity between the first and third month from the onset of the disease. There were no adverse events related to the administration of aspirin.Conclusion: The results indicate that treatment with low-dose aspirin may result in more rapid visual rehabilitation with fewer recurrences in patient with CSCR compared with untreated historic controls. The effectiveness of treatment with aspirin supports our hypothesis regarding the role of impaired fibrinolysis and increased platelet aggregation in the choriocapillaris in the pathogenesis of CSCR.Keywords: central serous chorioretinopathy, aspirin, plasminogen activator inhibitor 1, macula
format	article
author	Antonio Caccavale Filippo Romanazzi Manuela Imparato et al
author_facet	Antonio Caccavale Filippo Romanazzi Manuela Imparato et al
author_sort	Antonio Caccavale
title	Low-dose aspirin as treatment for central serous chorioretinopathy
title_short	Low-dose aspirin as treatment for central serous chorioretinopathy
title_full	Low-dose aspirin as treatment for central serous chorioretinopathy
title_fullStr	Low-dose aspirin as treatment for central serous chorioretinopathy
title_full_unstemmed	Low-dose aspirin as treatment for central serous chorioretinopathy
title_sort	low-dose aspirin as treatment for central serous chorioretinopathy
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/df09e4699ca4414d864fbdb0844326de
work_keys_str_mv	AT antoniocaccavale lowdoseaspirinastreatmentforcentralserouschorioretinopathy AT filipporomanazzi lowdoseaspirinastreatmentforcentralserouschorioretinopathy AT manuelaimparato lowdoseaspirinastreatmentforcentralserouschorioretinopathy AT etal lowdoseaspirinastreatmentforcentralserouschorioretinopathy
_version_	1718399486684823552

Low-dose aspirin as treatment for central serous chorioretinopathy

Ejemplares similares